A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

Inclusion Criteria:

- Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), prior to the first administration of study intervention

- Total body surface area (BSA) greater than or equal to (>=)10 percent (%) at screening and baseline

- Total psoriasis area and severity index (PASI) >=12 at screening and baseline

- Total investigator global assessment (IGA) >=3 at screening and baseline

- Candidate for phototherapy or systemic treatment for plaque psoriasis

Exclusion Criteria:

- Nonplaque form of psoriasis (for example [e.g.], erythrodermic, guttate, or pustular)

- Current drug-induced psoriasis (e.g., a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)

- Known allergies, hypersensitivity, or intolerance to JNJ-77242113, ustekinumab, or its excipients

- Major surgical procedure within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study

- Transplanted organ (with exception of a corneal transplant greater than [>] 12 weeks before the first administration of study intervention)